2 results
Approved WMOCompleted
Primary:To demonstrate the non-inferior antiviral activity of CAB LA + RPV LA every two months compared to a BIK single tablet regimen administered once daily over 12 months in suppressed HIV-1 infected antiretroviral therapy (ART)-experienced…
Approved WMORecruiting
The primary objective is to investigate if IMO-2125 is capable of a) lowering the number of tumor positive SLN and b) inducing a loco-regional and systemic immune response. The secondary objective is to investigate RFS and OS at 18 months, 24 months…